IN8BIO Inc. has released a presentation detailing its ongoing research and development efforts, with a focus on harnessing the power of Gamma-Delta T cells. The presentation highlights the progress and scope of clinical trials for its product candidates, including INB-100, INB-200, INB-400, and INB-600. IN8BIO is also exploring opportunities for certain programs and preclinical assets, supported by the potential to receive additional capital from convertible securities. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.